BreitbachC.J., ArulanandamR., De SilvaN.et al.2013. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res.in press.
2.
CallejasD., MannC.J., AyusoE.et al.2013. Treatment of diabetes and long-term survival following insulin and glucokinase gene therapy. Diabetesin press.
3.
CideciyanA.V., AlemanT.S., BoyeS.L.et al.2008. Human gene therapy for RPE65-isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A., 105:15112–15117.
4.
CideciyanA.V., JacobsonS.G., BeltranW.A.et al.2013. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl. Acad. Sci. U.S.A., 110:E517–E525.
5.
HeoJ., ReidT., RuoL.et al.2013. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med.in press.
6.
JacobsonS.G., CideciyanA.V., RatnakaramR.et al.2011. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: Safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol., 130:9–24.
7.
National Eye Institute. 2013. New findings suggest need for combined strategy in treatment of rare form of blindness [Press release]www.nei.nih.gov/news/briefs/newfindings_blindness.asp
